Complete Genomics was founded in June 2005 by Clifford Reid, Radoje (Rade) Drmanac, and John Curson.

[3] The resulting data has supported research in diverse areas such as screening of embryos,[4] detection of genetic relationships,[5][6] neurology,[7] aging,[8] a novel Mendelian disease with neuromuscular and cardiac involvement,[9] eating disorders,[10] Prader-Willi syndrome and autism,[11] ophthalmology,[12] and oncology.

It enables phasing, SV detection, scaffolding, and cost-effective diploid de novo genome assembly from second-generation sequencing technology.

[21] After the acquisition, Complete Genomics moved to San Jose and in June 2018 became part of MGI.

[22] MGI was a subsidiary of BGI Group before it was spun out and listed on the Shanghai Stock Exchange in 2022.